Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept

다국어 초록 (Multilingual Abstract)

Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.

참고문헌 (Reference)

1 Shimizu A, "Ultrastructural changes in mice actively producing antibodies to desmoglein 3 parallel those in patients with pemphigus vulgaris" 294 : 318-323, 2002

2 Majzner RG, "Tumor antigen escape from CAR T-cell therapy" 8 : 1219-1226, 2018

3 Zhang W, "Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR" 17 : 2120-2123, 2021

4 Devauchelle-Pensec V, "Treatment of primary Sjögren syndrome with rituximab : a randomized trial" 160 : 233-242, 2014

5 Lallana EC, "Toxicities of immunosuppressive treatment of autoimmune neurologic diseases" 9 : 468-477, 2011

6 Bright RJ, "Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy : a systematic review" 14 : 26-, 2014

7 Watanabe S, "Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica" 13 : 128-132, 2007

8 Jin X, "Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus" 18 : 1896-1903, 2021

9 Lescoat A, "Therapeutic approaches to systemic sclerosis : recent approvals and future candidate therapies" 2021

10 Shlomchik MJ, "The role of B cells in lpr/lpr-induced autoimmunity" 180 : 1295-1306, 1994

11 Goodnow CC, "The need for central and peripheral tolerance in the B cell repertoire" 248 : 1373-1379, 1990

12 Brown S, "The TRACTISS protocol : a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren’s Syndrome" 15 : 21-, 2014

13 Dai Z, "T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape" 7 : 85-, 2022

14 Kansal R, "Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus" 11 : eaav1648-, 2019

15 Zografou C, "Short-and long-lived autoantibody-secreting cells in autoimmune neurological disorders" 12 : 686466-, 2021

16 Szyszko EA, "Salivary glands of primary Sjögren’s syndrome patients express factors vital for plasma cell survival" 13 : R2-, 2011

17 Ebata S, "Safety and efficacy of rituximab in systemic sclerosis(DESIRES) : a doubleblind, investigator-initiated, randomised, placebo-controlled trial" 3 : e489-e497, 2021

18 Tahara M, "Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders(RIN-1 study) : a multicentre, randomised, double-blind, placebo-controlled trial" 19 : 298-306, 2020

19 Tony HP, "Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases : experience from a national registry(GRAID)" 13 : R75-, 2011

20 Werth VP, "Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris" 384 : 2295-2305, 2021

21 Jones RB, "Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis : 2-year results of a randomised trial" 74 : 1178-1182, 2015

22 Stone JH, "Rituximab versus cyclophosphamide for ANCA-associated vasculitis" 363 : 221-232, 2010

23 Querol L, "Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins" 2 : e149-, 2015

24 Xiong A, "Rituximab in the treatment of immune-mediated necrotizing myopathy : a review of case reports and case series" 14 : 1756286421998918-, 2021

25 Rodrigo C, "Rituximab in the treatment of autoimmune haemolytic anaemia" 79 : 709-719, 2015

26 Garvey B, "Rituximab in the treatment of autoimmune haematological disorders" 141 : 149-169, 2008

27 Roux T, "Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases" 23 : 235-240, 2018

28 Eming R, "Rituximab exerts a dual effect in pemphigus vulgaris" 128 : 2850-2858, 2008

29 Ellebrecht CT, "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease" 353 : 179-184, 2016

30 Bowman SJ, "Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome" 69 : 1440-1450, 2017

31 Bekar KW, "Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus" 62 : 2443-2457, 2010

32 Hahn AF, "Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, shamcontrolled, cross-over study" 119 : 1055-1066, 1996

33 Nowak RJ, "Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis : the BeatMG study" 98 : e376-e389, 2021

34 Bhoj VG, "Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy" 128 : 360-370, 2016

35 Sanders SL, "Pemphigus and pemphigoid" 49 : 681-694, 1965

36 Kasperkiewicz M, "Pemphigus" 3 : 17026-, 2017

37 Yoshizaki A, "Pathogenic roles of B lymphocytes in systemic sclerosis" 195 : 76-82, 2018

38 Schett G, "OP0279 CAR-T cell treatment of refractory systemic lupus erythematosus-safety and preliminary efficacy data from the first four patients" 81 : 185-, 2022

39 Behin A, "New pathways and therapeutic targets in autoimmune myasthenia gravis" 5 : 265-277, 2018

40 Lazaridis K, "Myasthenia gravis : autoantibody specificities and their role in MG management" 11 : 596981-, 2020

41 Gilhus NE, "Myasthenia gravis" 5 : 30-, 2019

42 Oh SM, "Muscle-specific tyrosine kinase chimeric autoantibody receptor T cells(MuSK-CAART) : a precision cellular immunotherapy for antigen-specific B cell depletion in MuSK myasthenia gravis" 30 : 15-, 2022

43 Nemazee D, "Mechanisms of central tolerance for B cells" 17 : 281-294, 2017

44 Marino M, "Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis" 11 : 613-, 2020

45 Meng H, "La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease" 192 : 40-49, 2018

46 Cree BAC, "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder(N-MOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial" 394 : 1352-1363, 2019

47 Bruce IN, "Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus" 11 : 765-777, 2022

48 Marda A, "Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART"

49 Joly P, "First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus(Ritux 3) : a prospective, multicentre, parallel-group, open-label randomised trial" 389 : 2031-2040, 2017

50 Tebbe B, "Epidemiology and socioeconomic impact of skin disease in lupus erythematosus" 6 : 96-104, 1997

51 Jordan S, "Effects and safety of rituximab in systemic sclerosis : an analysis from the European Scleroderma Trial and Research(EUSTAR)group" 74 : 1188-1194, 2015

52 Murphy G, "Effect of gender on clinical presentation in systemic lupus erythematosus" 52 : 2108-2115, 2013

53 Poole BD, "Early targets of nuclear RNP humoral autoimmunity in human systemic lupus erythematosus" 60 : 848-859, 2009

54 Li P, "Drugs for autoimmune inflammatory diseases : from small molecule compounds to anti-TNF biologics" 8 : 460-, 2017

55 Pan J, "Donor-derived CD7chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia : first-in-human, phase I trial" 39 : 3340-3351, 2021

56 Stuhlmüller B, "Disease specific autoantibodies in idiopathic inflammatory myopathies" 10 : 438-, 2019

57 Litchman T, "Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients : a single-center retrospective study" 411 : 116690-, 2020

58 Wolbert J, "Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies" 5 : e132411-, 2020

59 Mueller KT, "Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia" 130 : 2317-2325, 2017

60 Stachowiak S, "Cartesian therapeutics to present late-breaking data from phase 1/2a trial of RNA CAR T-cell therapy in patients with generalized myasthenia gravis"

61 Moll M, "CD7-negative helper T cells accumulate in inflammatory skin lesions" 102 : 328-332, 1994

62 Gomes-Silva D, "CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies" 130 : 285-296, 2017

63 Schmidt D, "CD4+ CD7-CD28-T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity" 97 : 2027-2037, 1996

64 Mougiakakos D, "CD19-targeted CAR T cells in refractory systemic lupus erythematosus" 385 : 567-569, 2021

65 Jayaraman J, "CAR-T design : elements and their synergistic function" 58 : 102931-, 2020

66 Chowdhury F, "Biological therapy in primary Sjögren’s syndrome: effect on salivary gland function and inflammation" 8 : 707104-, 2021

67 Rosman Z, "Biologic therapy for autoimmune diseases : an update" 11 : 88-, 2013

68 Reddy V, "B-cell depletion in SLE : clinical and trial experience with rituximab and ocrelizumab and implications for study design" 15 (15): S2-, 2013

69 Julie Mielle, "B cells in Sjögren’s syndrome: from pathophysiology to therapeutic target" Oxford University Press (OUP) 60 (60): 2545-2560, 2019

70 Cornec D, "B cells in Sjögren’s syndrome : from pathophysiology to diagnosis and treatment" 39 : 161-167, 2012

71 Lee DS, "B cell depletion therapies in autoimmune disease : advances and mechanistic insights" 20 : 179-199, 2021

72 Jacob N, "B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice" 186 : 4984-4993, 2011

73 Bishu S, "Autoimmune enteropathy with a CD8+ CD7-T-cell small bowel intraepithelial lymphocytosis : case report and literature review" 11 : 131-, 2011

74 Stathopoulos P, "Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis" 2 : e94263-, 2017

75 Fayyaz A, "Autoantibodies in Sjögren’s syndrome" 42 : 419-434, 2016

76 Amagai M, "Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion" 67 : 869-877, 1991

77 Waters P, "Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis" 65 : 913-919, 2008

78 Lee J, "Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris" 130 : 6317-6324, 2020

79 Lunardon L, "Adjuvant rituximab therapy of pemphigus : a single-center experience with 31 patients" 148 : 1031-1036, 2012

80 Yaniv G, "A volcanic explosion of autoantibodies in systemic lupus erythematosus : a diversity of 180 different antibodies found in SLE patients" 14 : 75-79, 2015

81 Chang DJ, "A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris(mPV)patients : early cohort clinical and translational data" 142 : S1-, 2022

82 Daoussis D, "A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease" 46 : 625-631, 2017